The George Institute For Global Health
United Kingdom


Heerspink HJL, Perkovic V. Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease: Moving from Single Trials to an Ongoing Platform. Clin J Am Soc Nephrol. 2018;13(6):946-948. doi:10.2215/CJN.01290118.
Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program. Circulation. 2018. doi:10.1161/CIRCULATIONAHA.118.035901.
Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018. doi:10.1016/S2213-8587(18)30141-4.
Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323-334. doi:10.1161/CIRCULATIONAHA.117.032038.
Mohammedi K, Chalmers J, Herrington W, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018;8(1):7. doi:10.1038/s41387-017-0012-y.
Heerspink HJL, Andress DL, Bakris G, et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018;20:1369 - 1376. doi:10.1111/dom.13245.
Liao J-L, van den Broek-Best O, Smyth B, et al. The effect of extended hours dialysis on sleep quality in a randomised trial. Nephrology (Carlton). 2018. doi:10.1111/nep.13236.
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018. doi:10.1161/CIRCULATIONAHA.118.034222.
Rosenstock J, Perkovic V, Alexander JH, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio. Cardiovasc Diabetol. 2018;17(1):39. doi:10.1186/s12933-018-0682-3.
Heerspink HJL, Andress DL, Bakris G, et al. Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial. Diabetes Obes Metab. 2018. doi:10.1111/dom.13315.
John O, Ohkuma T, Zoungas S, et al. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes Care. 2018;41(1):163-170. doi:10.2337/dc17-1467.
Pecoits-Filho R, Perkovic V. Are SGLT2 Inhibitors Ready for Prime Time for CKD?. Clin J Am Soc Nephrol. 2018;13(2):318-320. doi:10.2215/CJN.07680717.
Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099. doi:10.1056/NEJMc1712572.
Jardine M, Mahaffey KW, Neal B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017;46(6):462-472. doi:10.1159/000484633.
Baigent C, Herrington WG, Coresh J, et al. Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;92(2):297-305. doi:10.1016/j.kint.2017.04.019.
Ren S, Wang Y, Xian L, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. PLoS One. 2017;12(9):e0184398. doi:10.1371/journal.pone.0184398.
Marx N, McGuire DK, Perkovic V, et al. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. Diabetes Care. 2017;40(9):1144-1151. doi:10.2337/dc17-0068.
Lv J, Zhang H, Wong MGeot, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017;318(5):432-442. doi:10.1001/jama.2017.9362.
Yu J, Zhou Z, R McEvoy D, et al. Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis. JAMA. 2017;318(2):156-166. doi:10.1001/jama.2017.7967.
Gummer J, Trengove R, Pascoe EM, et al. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology (Carlton). 2017;22(7):548-554. doi:10.1111/nep.12815.
Heerspink HJL, Makino H, Andress D, et al. Comparison of exposure response relationship of atrasentan between North American and Asian populations. Diabetes Obes Metab. 2017;19(4):545-552. doi:10.1111/dom.12851.
Jun M, James MT, Ma Z, et al. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis. 2017;69(6):734-743. doi:10.1053/j.ajkd.2016.10.018.
Pena MJ, de Zeeuw D, Andress D, et al. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes Obes Metab. 2017;19(5):749-753. doi:10.1111/dom.12864.
Liyanage T, Ninomiya T, Perkovic V, et al. Chronic kidney disease in Asia: Protocol for a collaborative overview. Nephrology (Carlton). 2017;22(6):456-462. doi:10.1111/nep.12821.
Groop P-H, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610-1619. doi:10.1111/dom.13041.